Integra LifeSciences Holdings Corporation (IART) is well-poised to grow in the coming quarter, driven by healthy sales growth within its Tissue Technologies business despite product recall and manufacturing pause in Boston. The strong performance of the company's Codman Specialty Surgical (CSS) arm is encouraging. Meanwhile, headwinds such as a dull macro environment and currency fluctuations pose concerns for Integra's operations. In the past year, this Zacks Rank #3 (Hold) stock has lost 55.1% against the ...